CLINICAL TRIALS PROFILE FOR JEUVEAU
✉ Email this page to a colleague
All Clinical Trials for JEUVEAU
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04715048 ↗ | Split-Face Study Comparing Botox and Jeuveau in Treating Glabellar Lines | Not yet recruiting | University of Southern California | Early Phase 1 | 2021-01-01 | The purpose of this study is to compare the efficacy and side effects of Botox and Jeuveau for glabellar lines. |
| NCT05129319 ↗ | Jeuveau Treatment of Glabellar Lines Using OLD Versus COLD | Not yet recruiting | Evolus, Inc. | Early Phase 1 | 2021-11-01 | This is a blinded, randomized study in the US to compare the duration response of two different concentrations of Jeuveau in healthy female subjects with moderate to severe dynamic glabellar lines on maximum frown. |
| NCT05129319 ↗ | Jeuveau Treatment of Glabellar Lines Using OLD Versus COLD | Not yet recruiting | Clinical Testing of Beverly Hills | Early Phase 1 | 2021-11-01 | This is a blinded, randomized study in the US to compare the duration response of two different concentrations of Jeuveau in healthy female subjects with moderate to severe dynamic glabellar lines on maximum frown. |
| NCT05167864 ↗ | Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area | Not yet recruiting | University of Pennsylvania | N/A | 2022-01-15 | The purpose of the study is to use 3D imaging to evaluate the effects of four FDA approved neuromodulators on facial lines, wrinkles and animation. Participation is available to women who have never had a cosmetic procedure above the malar region nor a treatment with a neuromodulator within 12 months. All subjects will undergo 3D imaging using the VECTRA M3 (Canfield Scientific, Inc, Fairfield, NJ) prior to treatment with a neuromodulator in order to determine their baseline dimensions. Imaging will be repeated post injection to determine change over time. |
| NCT05320393 ↗ | Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines | Recruiting | ethica Clinical Research Inc. | Phase 2 | 2022-03-30 | The purpose of this study is to demonstrate the safety and duration of effect of 40 Units of prabotulinumtoxinA-xvfs (Jeuveau®) in providing temporary improvement in the appearance of moderate to severe glabellar lines (frown lines, which are the vertical lines that develop between the eyebrows) in adult participants. It will also determine if the duration of effect of 40 Units of Jeuveau® is greater than that of 20 Units of Jeuveau® and 20 Units of Botox® Cosmetic. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for JEUVEAU
Condition Name
Clinical Trial Locations for JEUVEAU
Trials by Country
Clinical Trial Progress for JEUVEAU
Clinical Trial Phase
Clinical Trial Sponsors for JEUVEAU
Sponsor Name
